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Abstract
Focal adhesion kinase (FAK) is known to be located at the intersection between extracellular matrix and growth factor
signaling pathways to regulate cell motility. We have shown previously that an activated form (BCR-FLTm1) of Flt-1 kinase,
a receptor for vascular endothelial growth factor, had a tubulogenic activity not only in endothelial cells but also in
fibroblastic cells. Here we show that tubulogenesis by BCR-FLTm1 depends on FAK and that FAK tyrosine
phosphorylation and association with an activated Flt-1 receptor complex is increased after vascular endothelial growth
factor stimulation of NIH3T3 cells overexpressing Flt-1. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Focal adhesion kinase (FAK) is a nonreceptor ty-
rosine kinase which integrates signals from extracel-
lular matrix (ECM) and cytokines, and has been
shown to play a pivotal role in the turnover of focal
adhesions and actin polymerization that coordinately
result in cell motility [1,2]. Knockout mice of FAK
displayed embryonic lethality due to mesodermal de-
fect in the late phase of gastrulation with a variety of
abnormalities including poor vasculature [1,3]. Dis-
continuity in dorsal aorta was present and no blood
cells were found in embryonic heart or vasculature,
suggesting a defect in vasculogenesis which has been
suggested to be driven by ECM. Biological experi-
ments using ¢broblastic cells derived from FAK
knockout mice have postulated that cell motility
was abrogated in those cells. Formation of blood
islands was not impaired in FAK knockout mice.
Recently vascular endothelial growth factor
(VEGF) has been claimed to activate FAK through
KDR to induce endothelial cell migration [4,5].
KDR-de¢cient mice lack blood islands and therefore
the VEGF/KDR system has been shown to be essen-
tial for development of hemangioblasts from their
progenitors at the earlier developmental stage [6].
Mice de¢cient in another receptor for VEGF, Flt-
1, retained their ability to develop blood islands but
assembly of endothelial cells was disturbed which
resulted in the disorganized vascular architecture
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[7]. The only defect initially found in mice in which
the tyrosine kinase domain of Flt-1 had been deleted
was a poor ability in migration of macrophages that
exceptionally express a VEGF receptor Flt-1 [8], but
this has left the fundamental question of what the
biological functions are in a ligand-induced activa-
tion of Flt-1. Di⁄culties in studying the function of
Flt-1 have been that expression of endogenous Flt-1
cannot be maintained in endothelial cells in primary
culture which include well-known human umbilical
vein endothelial cells (HUVEC) and that its exoge-
nous expression with usual expression vectors can be
hardly tolerated in mammalian cells at a level high
enough to exert biological activities [9]. In order to
overcome those obstacles, we have reported previ-
ously a NIH3T3 cell line that overexpress Flt-1
(3T3/Flt-1) with a papilloma virus vector [10]. Sig-
ni¢cant activation of Flt-1 could be induced with the
addition of VEGF and we have observed morpho-
genic activities when 3T3/Flt-1 cells were plated onto
basement membrane matrix (Matrigel) in the pres-
ence of VEGF [11]. We have also established a con-
stitutively activated form of Flt-1 kinase in a ligand-
independent fashion. This arti¢cial kinase BCR-
FLTm1 has been shown to have a tubulogenic po-
tential not only in endothelial cells but also in ¢bro-
blasts that were established from embryo [11,12].
Molecular mechanisms that underlie tubulogenic be-
haviors of endothelial cells are poorly understood.
By expressing BCR-FLTm1 in FAK-de¢cient and
control cells, here we show for the ¢rst time that
an interaction between Flt-1 and FAK plays an im-
portant role for tubulogenesis.
2. Materials and methods
2.1. Cell culture
The FAK-de¢cient cell line derived from embryos
of FAK knockout mice and the control cell line from
wild type mice established in a similar fashion were
kindly provided by Dr. T. Yamamoto at the Institute
of Medical Science, University of Tokyo [1]. Those
cells and FAK-de¢cient cells transfected with either
Tet-FAK (wild type) or -FAK(F397) [13] were cul-
tured in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum
(FCS). The rat sinusoidal endothelial cell lines
NP31 expressing mock or BCR-FLTm1 were de-
scribed before [14] and were cultured in DMEM/
10% FCS. BCR-FLTm1 is an arti¢cial chimeric mol-
ecule in which the kinase domain of Flt-1 is consti-
tutively activated by fusion to the BCR sequence
with an oligomerizing property. NIH3T3 cells which
overexpress mock or FLT-1 were cultured in
DMEM/5% calf serum, and VEGF stimulation ex-
periments were performed as described previously
[10]. Brie£y, cells were starved of serum for 10 h
and stimulated with VEGF at 20 ng/ml for 5 min.
Introduction of the BCR-FLTm1 gene by retrovirus-
mediated gene transfer was performed as described
before [11]. Approx. 104^105 cells in a 6 cm dish were
infected with 1 ml of retrovirus for 1 h, and cultures
were continued for 48 h by adding 4 ml of fresh
medium (acute infection). Colonies derived from a
single cell were isolated by splitting an acutely in-
fected population of cells. In 2 weeks the expression
of BCR-FLTm1 was examined by Western blotting
(stable cell lines). Matrigel cultures were performed
by plating approx. 104 stable cell lines onto 300 Wl of
Matrigel presolidi¢ed at 37‡C in 24 wells containing
1 ml of DMEM with 10% FCS. Matrigel cultures
were usually continued for 4 weeks without changing
medium [12]. Tubulogenic ability was quantitated
3 weeks after starting Matrigel culture by counting
extended cords that were longer than 50 Wm in at
least three independent experiments.
2.2. Molecular analyses
Anti-Flt-1 antibody was described before [10] and
anti-FAK antibody was purchased from Transduc-
tion Laboratory. Anti-phosphotyrosine antibody
PY20 was purchased from ICN. Western blotting
was performed as described previously [12]. Cells
were lysed on ice in protein extraction bu¡er contain-
ing 50 mM HEPES, pH 7.5, 150 mM NaCl, 1%
Triton X-100, 1 mM PMSF, 10 mM sodium pyro-
phosphate, 5 mM EDTA, and 2 mM sodium ortho-
vanadate. For immunoprecipitation, cell lysates were
incubated with antibody prebound to protein A-Se-
pharose beads for 2 h. Immunoprecipitates were then
washed twice in the same protein extraction bu¡er.
The intensity of bands in Western blotting was rela-
tively quantitated by NIH image.
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3. Results
We have established previously a retrovirus that
expresses a constitutively activated form of the Flt-
1 kinase BCR-FLTm1. In this arti¢cial chimera the
ABL kinase domain of the human leukemia onco-
gene BCR-ABL was replaced with the kinase domain
of the receptor Flt-1 with upregulating point muta-
tions within the Flt-1 sequence. BCR-FLTm1 has
been shown to have a tubulogenic potential in Rat1
¢broblasts and the NP31 sinusoidal endothelial cell
line [12]. In order to address to the question of
whether or not the tubulogenic activity is dependent
on FAK, we have retrovirally introduced BCR-
FLTm1 in FAK-de¢cient ¢broblastic cells (FAK3/
3) (see Fig. 1A, lower panel for no expression of
FAK in FAK3/3 cells) and its control cell line
(FAK+/+) established in a similar manner. For con-
trols, those cell lines were also infected with retrovi-
ruses expressing mock. The expression levels of the
BCR-FLTm1 protein in FAK+/+ cells and FAK3/3
cells were roughly equivalent as shown in Fig. 1A
(upper panel, lanes 3 and 4). When the parental
FAK-de¢cient and control cells were plated onto
Matrigel, they did not show branching morphogene-
sis and grew as cell aggregates. However, prominent
extensions of cords were observed in control cells but
not in FAK-de¢cient cells when BCR-FLTm1 was
expressed. When tubulogenic ability was quantitated
at 3 weeks by counting cords longer than 50 Wm in
24 wells (tubulogenic score), FAK+/+/BCR-FLTm1
cells had a mean score of 263 þ 20.5, while FAK+/+
Fig. 1. BCR-FLTm1 cannot exert a tubulogenic ability in FAK-de¢cient cells. (A) Anti-Flt-1 immunoprecipitates (upper panel) or to-
tal cell lysates (lower panel) from control (lanes 1 and 3) or FAK-de¢cient cells (lanes 2 and 4) with (lanes 3 and 4) or without (lanes
1 and 2) expression of BCR-FLTm1 were subjected to anti-phosphotyrosine (upper panel) and anti-FAK (lower panel) Western blot-
ting. (B) The same set of cells (lane numbers in A correspond to picture numbers) were plated onto Matrigel and pictures were taken
after 2 weeks (scale bar 50 Wm). Cross-sections of BCR-FLTm1 expressers with hematoxylin^eosin staining are shown in the lower
panel in (3) and (4) (scale bar 10 Wm). Arrows indicate lumens.
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cells without BCR-FLTm1 and FAK3/3 cells with
or without BCR-FLTm1 had scores less than 10, in
three independent experiments. Histological sections
with hematoxylin^eosin staining revealed that cords
observed in control cells that expressed BCR-FLTm1
had lumens that contained no Matrigel (Fig. 1B(3),
lower panel). BCR-FLTm1-expressing FAK-de¢cient
cells appeared randomly aligned with no particular
structures.
In order to tested if tubulogenesis could be re-
stored to FAK-de¢cient cells when FAK was intro-
duced back, we have utilized FAK-de¢cient cells
with inducible expression of either wild type FAK
(Tet-FAK) or an autophosphorylation mutant F397
(Tet-FAK 397F) under a tetracycline repression sys-
tem [13]. With this system we have shown previously
that FAK autophosphorylation is required for cell
migration as judged by Boyden chamber assay [13].
As shown in Fig. 2, the BCR-FLTm1-mediated mor-
phogenic activity was evident in FAK-de¢cient cells
with expression of wild type FAK (FAK3/3/FAK-
WT/BCR-FLTm1) (tubulogenic score 211+26.2),
while the tubulogenic score of FAK3/3/FAK-WT
cells without BCR-FLTm1 was less than 10. Histo-
logical examinations revealed similar lumen forma-
tions as observed in Fig. 1B (data not shown).
FAK 397F expresser (FAK3/3/FAK-F397/BCR-
FLTm1) showed a slight recovery of tubulogenic ac-
tivity with a score of 36.3 þ 14.9. The tubulogenic
score was less than 10 when cells were plated onto
Matrigel after Tet-mediated downregulation of the
expression of FAK or FAK 397F (data not shown)
was accomplished.
Since the tubulogenic activity of BCR-FLTm1 was
dependent on FAK, we examined molecular interac-
tions between endogenously expressed FAK and exo-
genously introduced BCR-FLTm1 in the nontubulo-
genic endothelial cell line NP31 and tubulogenic
NP31 that expressed BCR-FLTm1. As shown in
Fig. 3A, anti-FAK immunoprecipitates contained
Fig. 2. Expression of the autophosphorylation site mutant of FAK cannot restore the tubulogenic activity to FAK3/3/BCR-FLTm1
cells. FAK-de¢cient cells transfected with Tet-FAK wild type (WT) (1, 3) or FAK-F397 (2, 4) with (3, 4) or without (1, 2) infection
by BCR-FLTm1 were plated onto Matrigel and pictures were taken after 2 weeks (scale bar 100 Wm).
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BCR-FLTm1, suggesting the presence of an interac-
tion between those two proteins. However, there
seemed to be no dramatic di¡erence in phospho-
tyrosine content of FAK between mock and BCR-
FLTm1 expressers.
Challenges to detect a physical binding between
the endogenous Flt-1 and FAK in HUVEC were
unsuccessful possibly because expression of Flt-1 is
not high enough to allow positive results. Therefore
we have analyzed NIH3T3 cells that overexpress
exogenous Flt-1 (NIH3T3/Flt-1) reported previously
[10]. In those cells we observe a baseline level of
autophosphorylation of Flt-1 without stimulation
by VEGF (Fig. 3C, upper panel, lane 1). We suppose
that this is due to the endogenous expression of
VEGF in NIH3T3/Flt-1 cells and to the overexpres-
sion of the receptor. VEGF stimulation caused a
5^6-fold increase of autophosphorylation as shown
in the upper panel in Fig. 3C. The anti-Flt-1 anti-
body appears to bind to a small amount of FAK
nonspeci¢cally (Fig. 3C, lane 1, lower panel) because
it pulls down the FAK protein in NIH3T3 cells
which lacks Flt-1 expression (data not shown). How-
ever, the amount of FAK which appeared to be
bound to Flt-1 was increased by roughly 2-fold
over the baseline when Flt-1 was activated (Fig.
3C, lane 2, lower panel), suggesting VEGF-induced
association, whether direct or indirect, between Flt-1
and FAK. When anti-FAK immunoprecipitates were
analyzed, the phosphotyrosine content of FAK was
also augmented by approx. 2-fold and the activated
Flt-1 was recruited with FAK (Fig. 3B). This infor-
mation postulates the presence of physical interac-
tions between FAK and the Flt-1, which can be
modi¢ed by VEGF stimulation.
4. Discussion
FAK has almost established its role as a signaling
molecule for cell motility by locating at the crossroad
between ECM and growth factor signaling [1]. Here
we show that FAK is required for morphogenesis or
tubulogenesis induced by the expression of a consti-
tutively activated form of Flt-1 in our biological sys-
tem. This may supportively explain the abnormalities
in vasculature, especially the discontinuity of endo-
thelial cells in large vessels in FAK knockout mice.
MDCK cells are well known for their ability to
form tubules in response to hepatocyte growth factor
(HGF) stimulation. Overexpression of FAK has been
reported to in£uence neither growth in dishes nor
branching morphogenesis of those cells in collagen
gels [15]. It may be interesting to see the e¡ect of
the absence of FAK on those two biological activities
in collagen gels.
We could observe that FAK is not only associated
with VEGF-activated Flt-1 complex but also appears
to be tyrosine-phosphorylated on VEGF stimulation
in the background of NIH3T3 cells overexpressing
Flt-1. However, considering that we have not suc-
ceeded in directly detecting Flt-1 in the anti-FAK
immune complex, the FAK/Flt-1 interaction could
be indirect. BCR-FLTm1 could not induce tubulo-
Fig. 3. Interaction between Flt-1 and FAK. (A) Anti-FAK im-
munoprecipitates from NP31 cells expressing mock (lane 1) or
BCR-FLTm1 (lane 2) were subjected to anti-phosphotyrosine
(PY) (upper panel) and anti-FAK (lower panel) Western blot-
ting. An arrow indicates the autophosphorylated BCR-FLTm1
protein coimmunoprecipitated with FAK. (B) Anti-FAK immu-
noprecipitates from NIH3T3 cells that overexpress Flt-1 before
(V 3) (lane 1) or after (V +) (lane 2) stimulation by VEGF
were subjected to anti-PY (upper and middle panels) and anti-
FAK (lower panel) Western blotting. The middle panel is a
short exposure of the upper panel showing the tyrosine-phos-
phorylated FAK. An arrow indicates autophosphorylated Flt-1
coimmunoprecipitated with FAK after VEGF stimulation. (C)
Anti-Flt-1 immunoprecipitates from the same set of cell lysates
as in B were subjected to anti-PY (upper panel) and anti-FAK
(lower panel) Western blotting.
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genesis completely in FAK3/3 cells expressing
FAK-F397. This implies that tubulogenesis could
be dependent on FAK phosphorylation. Flt-1 and
KDR are the currently known receptors for VEGF
that have tyrosine kinase activities, and VEGF has
recently been shown to induce KDR-mediated tyro-
sine phosphorylation of FAK [4,5]. This raises sev-
eral questions of why the phosphotyrosine content of
FAK was not enhanced in BCR-FLTm1 expressers.
A recent report postulated that the kinase activity by
itself of FAK is not required in FAK-dependent cell
migration by platelet-derived and epidermal growth
factors but that phosphorylation of FAK by Src is
indispensable [2]. It is known that FAK is constitu-
tively phosphorylated in v-Src-transformed cells.
This may be not only because c-Src is the physiolog-
ical enzyme responsible for FAK phosphorylation in
ECM signaling but also because v-Src is attached to
the membrane by myristylation [16]. Lack of mem-
brane association in BCR-FLTm1 may diminish the
stoichiometry of interaction with FAK.
In addition to Src two molecules, Shc and uPA
(urokinase-type plasminogen activator), have re-
cently been shown to be involved in FAK activation.
In integrin-stimulated signaling pathways FAK and
c-Src have been postulated to be independently acti-
vated, and FAK is capable of directly phosphorylat-
ing Shc at least in vitro [17]. In our tubulogenesis
system in vitro Shc was found to be constitutively
tyrosine-phosphorylated with recruitment of Grb2
in cells that participated in the accomplished tubular
architecture [12]. Matrigel contains growth factors
such as basic ¢broblast growth factor (bFGF) and
it was not surprising that Shc was found to be tyro-
sine-phosphorylated in FAK-de¢cient cells by Matri-
gel (data not shown). However, in FAK-de¢cient
cells tyrosine-phosphorylated Shc cannot bind to
FAK to promote further signaling.
uPA has been shown to induce FAK activation
[18]. Increased uPA activity in endothelial cells trans-
formed by the polyoma middle T oncogene has been
reported to be responsible for their alteration in mor-
phogenic behavior from tube to cyst formation [19].
The broad-spectrum serine protease inhibitor aproti-
nin can restore tube-forming ability back to those
cells, which was never observed in uPA-de¢cient cells
[20]. Induction of both uPA and uPA receptor by
VEGF has been reported in endothelial cells
[21,22]. We have observed no di¡erence in the ex-
pression of uPA receptor between mock and BCR-
FLTm1 expressing NP31 cells (data not shown).
However, we have previously observed that the
uPA activity was constantly present in the condi-
tioned media of NP31/BCR-FLTm1 cells in Matrigel
culture and addition of a serine protease inhibitor
e⁄ciently inhibited invading tubulogenesis of NP31/
BCR-FLTm1 cells in Matrigel [12]. This information
suggests that not only the interaction between the
BCR-FLTm1 and FAK but also expression of active
uPA and its receptor may contribute to the FAK-
dependent tubulogenic activity in BCR-FLTm1.
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